Insmed
INSM
NASDAQ
IPO2000
about INSM
Insmed focuses on developing innovative treatments for rare diseases, primarily advancing its lead product Clazakizumab, a humanized monoclonal antibody targeting immunoglobulin G (IgG) Fc receptors, currently under regulatory review and approved in certain regions for the treatment of immune thrombocytopenic purpura (ITP).
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $140.66 | $141.78 | $138.01 | $30.1B | 1.48M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$1.75 | n/a | n/a | -257.13% | -259.95% | 0% |